BeiGene, Ltd. (HKG: 6160)

Market Cap	160.89B
Revenue (ttm)	26.04B
Net Income (ttm)	-6.64B
Shares Out	n/a
EPS (ttm)	-63.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,580,400
Open	116.30
Previous Close	117.80
Day's Range	116.10 - 121.70
52-Week Range	75.45 - 153.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About BeiGene

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 10,600
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6160

Financial Performance

In 2023, BeiGene's revenue was 2.46 billion, an increase of 73.65% compared to the previous year's 1.42 billion. Losses were -881.71 million, -56.00% less than in 2022.

Financial numbers in CNY